These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 18650378)

  • 21. Engraftment of immune-deficient mice with primitive hematopoietic cells from beta-thalassemia and sickle cell anemia patients: implications for evaluating human gene therapy protocols.
    Larochelle A; Vormoor J; Lapidot T; Sher G; Furukawa T; Li Q; Shultz LD; Olivieri NF; Stamatoyannopoulos G; Dick JE
    Hum Mol Genet; 1995 Feb; 4(2):163-72. PubMed ID: 7757063
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of optimal expression cassette in retrovirus vector for beta-thalassemia gene therapy.
    Dong WJ; Li B; Liu DP; Zu ZX; Li J; Hao DL; Liu G; Guo ZC; Liang CC
    Mol Biotechnol; 2003 Jun; 24(2):127-40. PubMed ID: 12746554
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human beta-globin gene transfer.
    Rivella S; May C; Chadburn A; Rivière I; Sadelain M
    Blood; 2003 Apr; 101(8):2932-9. PubMed ID: 12480689
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correction of beta-thalassemia major by gene transfer in haematopoietic progenitors of pediatric patients.
    Roselli EA; Mezzadra R; Frittoli MC; Maruggi G; Biral E; Mavilio F; Mastropietro F; Amato A; Tonon G; Refaldi C; Cappellini MD; Andreani M; Lucarelli G; Roncarolo MG; Marktel S; Ferrari G
    EMBO Mol Med; 2010 Aug; 2(8):315-28. PubMed ID: 20665635
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correction of phenotype in a thalassemia mouse model using a nonmyeloablative marrow transplantation regimen.
    Bradley MB; Sattler RM; Raftopoulos H; Ward M; Grossman IR; Townes TM; Ryan TA; Bank A
    Biol Blood Marrow Transplant; 2002; 8(8):453-61. PubMed ID: 12234171
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Progress toward the genetic treatment of the beta-thalassemias.
    Sadelain M; Lisowski L; Samakoglu S; Rivella S; May C; Riviere I
    Ann N Y Acad Sci; 2005; 1054():78-91. PubMed ID: 16339654
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correction of murine β-thalassemia after minimal lentiviral gene transfer and homeostatic in vivo erythroid expansion.
    Negre O; Fusil F; Colomb C; Roth S; Gillet-Legrand B; Henri A; Beuzard Y; Bushman F; Leboulch P; Payen E
    Blood; 2011 May; 117(20):5321-31. PubMed ID: 21436071
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lentiviral vector ALS20 yields high hemoglobin levels with low genomic integrations for treatment of beta-globinopathies.
    Breda L; Ghiaccio V; Tanaka N; Jarocha D; Ikawa Y; Abdulmalik O; Dong A; Casu C; Raabe TD; Shan X; Danet-Desnoyers GA; Doto AM; Everett J; Bushman FD; Radaelli E; Assenmacher CA; Tarrant JC; Hoepp N; Kurita R; Nakamura Y; Guzikowski V; Smith-Whitley K; Kwiatkowski JL; Rivella S
    Mol Ther; 2021 Apr; 29(4):1625-1638. PubMed ID: 33515514
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful treatment of murine beta-thalassemia intermedia by transfer of the human beta-globin gene.
    May C; Rivella S; Chadburn A; Sadelain M
    Blood; 2002 Mar; 99(6):1902-8. PubMed ID: 11877258
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A preclinical approach for gene therapy of beta-thalassemia.
    Breda L; Kleinert DA; Casu C; Casula L; Cartegni L; Fibach E; Mancini I; Giardina PJ; Gambari R; Rivella S
    Ann N Y Acad Sci; 2010 Aug; 1202():134-40. PubMed ID: 20712784
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Parallel assessment of globin lentiviral transfer in induced pluripotent stem cells and adult hematopoietic stem cells derived from the same transplanted β-thalassemia patient.
    Tubsuwan A; Abed S; Deichmann A; Kardel MD; Bartholomä C; Cheung A; Negre O; Kadri Z; Fucharoen S; von Kalle C; Payen E; Chrétien S; Schmidt M; Eaves CJ; Leboulch P; Maouche-Chrétien L
    Stem Cells; 2013 Sep; 31(9):1785-94. PubMed ID: 23712774
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vivo hematopoietic stem cell gene therapy ameliorates murine thalassemia intermedia.
    Wang H; Georgakopoulou A; Psatha N; Li C; Capsali C; Samal HB; Anagnostopoulos A; Ehrhardt A; Izsvák Z; Papayannopoulou T; Yannaki E; Lieber A
    J Clin Invest; 2019 Feb; 129(2):598-615. PubMed ID: 30422819
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia.
    Thompson AA; Walters MC; Kwiatkowski J; Rasko JEJ; Ribeil JA; Hongeng S; Magrin E; Schiller GJ; Payen E; Semeraro M; Moshous D; Lefrere F; Puy H; Bourget P; Magnani A; Caccavelli L; Diana JS; Suarez F; Monpoux F; Brousse V; Poirot C; Brouzes C; Meritet JF; Pondarré C; Beuzard Y; Chrétien S; Lefebvre T; Teachey DT; Anurathapan U; Ho PJ; von Kalle C; Kletzel M; Vichinsky E; Soni S; Veres G; Negre O; Ross RW; Davidson D; Petrusich A; Sandler L; Asmal M; Hermine O; De Montalembert M; Hacein-Bey-Abina S; Blanche S; Leboulch P; Cavazzana M
    N Engl J Med; 2018 Apr; 378(16):1479-1493. PubMed ID: 29669226
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Droplet digital polymerase chain reaction-based quantitation of therapeutic lentiviral vector copies in transduced hematopoietic stem cells.
    Phuphanitcharoenkun S; Bhukhai K; Phanthong P; Prasongtanakij S; Linn AK; Sutjarit N; Anurathapan U; Leboulch P; Payen E; Hongeng S; Borwornpinyo S
    Cytotherapy; 2024 Jun; 26(6):586-591. PubMed ID: 38551525
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plerixafor+G-CSF-mobilized CD34+ cells represent an optimal graft source for thalassemia gene therapy.
    Karponi G; Psatha N; Lederer CW; Adair JE; Zervou F; Zogas N; Kleanthous M; Tsatalas C; Anagnostopoulos A; Sadelain M; Rivière I; Stamatoyannopoulos G; Yannaki E
    Blood; 2015 Jul; 126(5):616-9. PubMed ID: 26089395
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Combination of CRISPR/Cas9 and iPSC Technologies in the Gene Therapy of Human β-thalassemia in Mice.
    Ou Z; Niu X; He W; Chen Y; Song B; Xian Y; Fan D; Tang D; Sun X
    Sci Rep; 2016 Sep; 6():32463. PubMed ID: 27581487
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Locus control region elements HS1 and HS4 enhance the therapeutic efficacy of globin gene transfer in beta-thalassemic mice.
    Lisowski L; Sadelain M
    Blood; 2007 Dec; 110(13):4175-8. PubMed ID: 17921347
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms leading to sustained reversion of beta-thalassemia in mice by doxycycline-controlled Epo delivery from muscles.
    Samakoglu S; Bohl D; Heard JM
    Mol Ther; 2002 Dec; 6(6):793-803. PubMed ID: 12498775
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transcriptional targeting of retroviral vectors to the erythroblastic progeny of transduced hematopoietic stem cells.
    Grande A; Piovani B; Aiuti A; Ottolenghi S; Mavilio F; Ferrari G
    Blood; 1999 May; 93(10):3276-85. PubMed ID: 10233879
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correction of β-thalassemia by CRISPR/Cas9 editing of the α-globin locus in human hematopoietic stem cells.
    Pavani G; Fabiano A; Laurent M; Amor F; Cantelli E; Chalumeau A; Maule G; Tachtsidi A; Concordet JP; Cereseto A; Mavilio F; Ferrari G; Miccio A; Amendola M
    Blood Adv; 2021 Mar; 5(5):1137-1153. PubMed ID: 33635334
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.